| 08.00 - 08.15 |
Welcome and introduction P-A. Abrahamsson, Malmö (SE) J. Baselga, Barcelona (ES) M. Baumann, Dresden (DE) M. Wirth, Dresden (DE) |
||
| 08.15 - 09.45 | Session 1: Imaging techniques in the diagnosis and staging of prostate cancer | ||
| Chairs: | B. Djavan, New York (US) R. Pötter, Vienna (AT) |
||
| 08.15 - 08.30 |
State-of-the-art lecture: What imaging does the surgeon need? A. Alcaraz, Barcelona (ES) |
 | |
| 08.30 - 08.45 |
State-of-the-art lecture: The need of the radiation oncologist in diagnosis and treatment planning A. Zietman, Boston (US) |
| |
| 08.45 - 09.00 |
State-of-the-art lecture: The role of sonography P. Hammerer, Braunschweig (DE) |
||
| 09.00 - 09.15 |
State-of-the-art lecture: The role of MRI J. Barentsz, Nijmegen (NL) |
| |
| 09.15 - 09.45 | Debate: Prostate cancer - To screen or not to screen | ||
| Moderators: |
P-A. Abrahamsson, Malmö (SE) A. Zietman, Boston (US) |
| |
| Pro: | T. Tammela, Tampere (FI) | | |
| Con: | F. Hamdy, Oxford (GB) | | |
| 09.45 - 10.15 | Coffee Break and Poster Viewing | ||
| 10.15 - 11.15 | Session 2: Controversies in the treatment of prostate cancer | ||
| Chairs: | P. Poortmans, Tilburg (NL) T. Tammela, Tampere (FI) |
||
| 10.15 - 10.45 | Round table session: Optimal treatment of locally advanced prostate cancer | ||
| Moderators: | T. Wiegel, Ulm (DE) P. Hammerer, Braunschweig (DE) |
||
|
What are the results of radiation therapy? R. Miralbell, Geneva (CH) |
| ||
|
What are the results of surgery? H. Van Poppel, Leuven (BE) |
| ||
| 10.45 - 11.15 | Round table session: Rising PSA after treatment with curative intent | ||
| Moderators: | M. Bolla, Grenoble (FR) H. Van Poppel, Leuven (BE) |
||
|
Optimal treatment of patients with a rising PSA after radical prostatectomy T. Wiegel, Ulm (DE) |
| ||
|
What should be the treatment after failure of radiotherapy? B. Djavan, New York (US) |
| ||
| 11.15 - 12.00 | Session 3: Novelties in prostate cancer | ||
| Chairs: | F. Hamdy, Oxford (GB) A. Zietman, Boston (US) |
||
| 11.15 - 11.30 |
State-of-the-art lecture: Post prostatectomy erectile dysfunction A. Briganti, Milan (IT) |
| |
| 11.30 - 11.45 |
State-of-the-art lecture: New hormonal therapies in prostate cancer V. Ravery, Paris (FR) |
| |
| 11.45 - 12.00 |
State-of-the-art lecture: Adjuvant treatment of prostate cancer J. Bellmunt, Barcelona (ES) |
||
| 12.00 - 13.30 | Lunch Break and Poster Viewing | ||
| 13.30 - 15.30 | Session 4: Diagnosis, prognosis and treatment of bladder cancer | ||
| Chairs: | T. De Reijke, Amsterdam (NL) M. Droller, New York (US) |
||
| 13.30 - 13.45 |
State-of-the-art lecture: Gene profiling in non-muscle invasive bladder cancer T. Orntoft, Aarhus (DK) |
| |
| 13.45 - 14.15 |
Debate: Urine markers are useful in the screening of bladder cancer Moderator: F. Debruyne, Nijmegen (NL) |
||
| Pro: | M. Droller, New York (US) | ||
| Con: | J. Witjes, Nijmegen (NL) | | |
| 14.15 - 14.30 |
State-of-the-art lecture: How to optimise the management of non-muscle invasive bladder cancer? T. De Reijke, Amsterdam (NL) |
| |
| 14.30 - 15.10 | Debate: The future of radical cystectomy is robotic surgery | ||
| Moderators: | F. Debruyne, Nijmegen (NL) H. Van Poppel, Leuven (BE) |
||
| Pro: | P. Wiklund, Stockholm (SE) | ||
| Con: | A. Alcaraz, Barcelona (ES) | | |
| 15.10 - 15.30 |
State-of-the-art lecture: Is there an optimal neobladder reconstruction? U. Studer, Berne (CH) |
| |
| 15.30 - 16.00 | Coffee Break and Poster Viewing | ||
| 16.00 - 17.30 | Session 5: Treatment of muscle-invasive bladder cancer | ||
| 16.00 - 16.40 | Point-counter-point: All patients with muscle-invasive bladder cancer should receive neoadjuvant radio- and/or chemotherapy | ||
| Moderators: | M. Babjuk, Prague (CZ) J. Bellmunt, Barcelona (ES) |
||
| Pro: | C. Rödel, Frankfurt (DE) | | |
| Con: | U. Studer, Berne (CH) | | |
| 16.40 - 17.15 |
Debate: Optimal treatment for patients over 75 (with use of audience response system) |
||
| Moderators: | M. De Santis, Vienna (AT) U. Studer, Berne (CH) |
||
|
Only surgical treatment M. Babjuk, Prague (CZ) |
| ||
|
Only radiation therapy A. Bossi, Villejuif (FR) |
| ||
| 17.15 - 17.30 |
State-of-the-art lecture: New systemic treatment modalities in advanced bladder cancer M. De Santis, Vienna (AT) |
| |
 |
 |
 |
 |